TY - JOUR
AU - Kurz, Carolin
AU - Carli, Laura
AU - Guersel, Selim
AU - Schrurs, Isabelle
AU - Jethwa, Alexander
AU - Carboni, Margherita
AU - Bittner, Tobias
AU - Hortsch, Sayuri
AU - Keeser, Daniel
AU - Brendel, Matthias
AU - Burow, Lena
AU - Haeckert, Jan
AU - Koriath, Carolin A M
AU - Tatò, Maia Lucia
AU - Utecht, Julia
AU - Papazov, Boris
AU - Morenas Rodriguez, Estrella
AU - Pogarell, Oliver
AU - Palleis, Carla
AU - Weidinger, Endy
AU - Stöcklein, Sophia
AU - Levin, Johannes
AU - Höglinger, Günter
AU - Rauchmann, Boris-Stephan
AU - Perneczky, Robert
TI - Plasma biomarkers of amyloid, tau </td><td width="150">
TI - amp; neuroinflammation in Alzheimer's disease and corticobasal syndrome.
JO - Archiv für Psychiatrie und Nervenkrankheiten
VL - 275
IS - 8
SN - 1433-8491
CY - Heidelberg
PB - Springer
M1 - DZNE-2025-01313
SP - 2255 - 2273
PY - 2025
AB - Blood-based biomarkers (BBBMs) could significantly facilitate the diagnosis of Alzheimer's disease (AD) and non-AD dementia by providing less invasive alternatives to cerebrospinal fluid (CSF) and positron emission tomography (PET) imaging.This study investigated how well the BBBMs-amyloid-β (Aβ) 1-42/1-40 ratio, phosphorylated tau181 (pTau181), apolipoprotein E4 (ApoE4), glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL)-reflect thorough clinical work-up validated by PET and CSF biomarkers in participants with AD (n = 27), Aβ-negative CBS (n = 26), and agematched healthy controls (HC) (n = 17).Factor and correlation explored biomarker associations. Bayesian regression, backward selection regression, and ROC curve analysis were applied to identify optimal biomarker combinations and diagnostic cut-offs.In AD cases, pTau181 and ApoE4 levels were elevated, and the Aβ1-42/1-40 ratio was reduced. ROC analysis showed high accuracy for pTau181, ApoE4 and Aβ1-42/1-40 in discriminating AD from HC, with a combination significantly improving performance. However, limited fold change, and high variability reduced the diagnostic applicability of Aβ1-42/1-40 ratio. Elevated NfL levels were the most reliable biomarker for CBS-Aβ(-) cases. GFAP showed limited discriminatory power due to overlapping levels, suggesting that it may not serve as a disease-specific biomarker but may be indicative of general neurodegeneration.This study highlights the diagnostic utility of pTau181, ApoE4 and the Aβ1-42/1-40 ratio for AD and NfL in the CBS-Aβ(-) cases and emphasizes the added value of combined biomarker models for group differentiation. Prospective studies will help validate these findings and refine clinical thresholds.
KW - Humans
KW - Alzheimer Disease: blood
KW - Alzheimer Disease: diagnosis
KW - tau Proteins: blood
KW - Female
KW - Amyloid beta-Peptides: blood
KW - Biomarkers: blood
KW - Aged
KW - Male
KW - Peptide Fragments: blood
KW - Glial Fibrillary Acidic Protein: blood
KW - Middle Aged
KW - Neurofilament Proteins: blood
KW - Neuroinflammatory Diseases: blood
KW - Apolipoprotein E4: blood
KW - Aged, 80 and over
KW - Corticobasal Degeneration: blood
KW - Corticobasal Degeneration: diagnosis
KW - Positron-Emission Tomography
KW - Apolipoprotein E (ApoE4) (Other)
KW - Beta-amyloid 1-40 (Aβ1-40) (Other)
KW - Beta-amyloid 1-42 (Aβ1-42) (Other)
KW - Glial fibrillary acidic protein (GFAP) (Other)
KW - Neurofilament light chain (NfL) (Other)
KW - Non-Alzheimer's disease dementia; beta (Other)
KW - Phosphorylated tau (pTau) (Other)
KW - tau Proteins (NLM Chemicals)
KW - Amyloid beta-Peptides (NLM Chemicals)
KW - Biomarkers (NLM Chemicals)
KW - Peptide Fragments (NLM Chemicals)
KW - Glial Fibrillary Acidic Protein (NLM Chemicals)
KW - Neurofilament Proteins (NLM Chemicals)
KW - Apolipoprotein E4 (NLM Chemicals)
KW - amyloid beta-protein (1-42) (NLM Chemicals)
KW - neurofilament protein L (NLM Chemicals)
KW - GFAP protein, human (NLM Chemicals)
KW - amyloid beta-protein (1-40) (NLM Chemicals)
KW - MAPT protein, human (NLM Chemicals)
LB - PUB:(DE-HGF)16
C6 - pmid:40314736
C2 - pmc:PMC12638345
DO - DOI:10.1007/s00406-025-02013-z
UR - https://pub.dzne.de/record/282550
ER -